Physician profile
Gregory Altemose
NPI 1366425431
$36,463.00
in general payments reported to CMS, 2019-2025
28 companies · $3,265 in 2025
The $3,265 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,090 · 2020: $2,747 · 2021: $14K · 2022: $2,771 · 2023: $4,682 · 2024: $2,249 · 2025: $3,265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,472 · Food and Beverage: $4,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,471.54 |
| Food and Beverage | $4,724.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14,310.21 | 2019-2025 | Ensite Precision, Cardiomems, Amplatzer Amulet |
| Topera, INC. | $9,045.92 | 2019-2021 | |
| Boston Scientific Corporation | $4,873.25 | 2019-2025 | Farapulse, Watchman Flx, Watchman |
| Medtronic, INC. | $4,505.86 | 2021-2025 | Micra, Pulseselect, Cobalt Dr Mri Surescan |
| Medtronic Vascular, INC. | $1,254.64 | 2019-2020 | |
| Atricure, INC. | $391.48 | 2019-2022 | |
| Cardiva Medical, INC. | $320.75 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $313.32 | 2019-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $304.23 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $199.51 | 2019-2021 | |
| Biosense Webster, INC. | $151.08 | 2024-2025 | Carto 3 |
| Pfizer INC. | $149.74 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.28 | 2020-2022 | |
| Biotronik INC. | $78.67 | 2023 | Selectra, Acticor 7 Vr-T Dx, Plexa Promri |
| Amgen INC. | $72.91 | 2020-2024 | Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $59.15 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $58.27 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $43.30 | 2021-2024 | Verquvo |
| Inari Medical, INC. | $42.85 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Portola Pharmaceuticals, LLC | $39.73 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.35 | 2021 | |
| Cordis US Corp. | $17.91 | 2024 | Mynx Control |
| Stryker Corporation | $17.52 | 2023 | N/A |
| Biosig Technologies, INC. | $16.48 | 2021 | |
| Cvrx, INC. | $16.45 | 2022 | |
| Chiesi USA, INC. | $13.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.31 | 2024 | Camzyos |
| Lundbeck LLC | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Altemose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.